Crystagen

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：  guangsheng 5   @zgguangsheng.com

1. Core Molecular & Physicochemical Specifications

2. Mechanism of Action

1. Thymic Function Regulation: Preserves thymic cortex - medulla structure, promotes thymocyte proliferation (via PCNA upregulation), and maintains thymic microenvironment integrity in aging/irradiated models.
2. T - Cell Subset Modulation: Increases CD3⁺, CD4⁺ T - cell counts, normalizes CD4⁺/CD8⁺ ratio, and enhances T - helper cell activity, which is crucial for cell - mediated immunity restoration.
3. Cytokine Balance: Reduces pro - inflammatory cytokine overexpression and elevates anti - inflammatory cytokines, mitigating chronic inflammation in secondary immunodeficiencies.
4. Epigenetic Regulation: Interacts with DNA/histones to promote heterochromatinization in lymphocytes, supporting immune cell homeostasis in the elderly.
5. Antioxidant & Anti - Aging: Reduces oxidative stress in immune cells and delays thymic involution, enhancing immune resilience with aging.

3. Biological Functions & Research Applications

3.1 Core Biological Effects

• Immune Restoration: Normalizes immunogram in 82% of patients with secondary immunodeficiencies (vs. 56% in control) and alleviates asthenic syndrome.
• T - Cell Enhancement: Targets T - cell immunity (CD3⁺/CD4⁺ elevation, CD4⁺/CD8⁺ balance) with milder effects on B lymphocytes.
• Radioprotection: Preserves thymic structure and promotes thymocyte proliferation in gamma - irradiated rats (accelerated aging model).
• Anti - Aging: Delays thymic aging and maintains immune cell function in elderly individuals.

3.2 Research & Clinical Applications

4. Production & Quality Control

4.1 Manufacturing Process

1. Solid - Phase Peptide Synthesis (SPPS): Fmoc chemistry assembles the Pro - Glu - Asp core sequence, purified via RP - HPLC to ≥99% purity.
2. Lyophilization: Freeze - drying forms stable powder, extending shelf - life and enabling cold - chain storage/transport.

4.2 Quality Testing Standards

5. Administration, Safety & Handling

5.1 Administration Routes & Dosage

• Oral Administration: Most common in clinical research; 1–2 capsules (10–20mg total) daily with meals for 10–30 days.
• Subcutaneous Injection: Research use; 500–1000 mcg/day (1–2 doses) for rapid immune restoration in animal models.

5.2 Safety Profile

• Low Toxicity: Transient mild gastrointestinal discomfort or headache (rare, dose - dependent, reversible).
• Non - Immunogenic: No allergic reactions reported in clinical studies; compatible with standard treatments.
• Contraindications: Hypersensitivity to Crystagen; pregnancy/lactation (limited data); caution in severe renal/hepatic dysfunction.

5.3 Handling Recommendations

• Storage: -20°C dry/dark environment; avoid light/moisture.
• Transport: Cold chain (2–8°C) to preserve stability.
• Research - Only Use: For R&D; not for human clinical use without regulatory approval.
• Disposal: Follow local chemical waste guidelines to prevent environmental contamination.

6. Advantages of High - Purity Crystagen Powder

1. Immune Targeting: High purity ensures specific thymic and T - cell modulation, minimizing off - target effects and ensuring consistent experimental results.
2. Geroprotective Potential: Preserves thymic function, which is a key advantage for aging - related immune research.
3. Clinical Compatibility: Low toxicity and no severe side effects make it suitable for combination with standard therapies in supportive care research.
4. Stable Activity: Low impurity content reduces degradation risk and maintains long - term biological activity.